Purpose To report long-term tumor control, toxicity, and functional outcomes after a second course of fractionated radiation therapy for recurrent craniopharyngioma previously treated with radiation therapy. Methods and Materials We identified all patients with craniopharyngioma with recurrent or progressive disease, unsuitable for further medical management or re-resection, who underwent 2 courses of fractionated photon radiation therapy at a single institution between 1998 and 2024. Reirradiation was delivered to 54 Gy in 30 fractions with full overlap of the initial target; dose constraints to optic nerves, chiasm, and brainstem were Dmax/D0.03cc (Maximum Dose or Dose to 0.03 cubic centimetres) ≤54 Gy. Outcomes were summarized descriptively. Results Six patients received reirradiation a mean of 9.8 years (range, 5.6-20.5) after initial radiation therapy (50-54 Gy in 25-30 fractions). Median follow-up after reirradiation was 4.1 years (range, 0.4-8.8). At the last follow-up, 4 patients were alive, all with local disease control (2 with radiological regression, 2 with stable disease). Two deaths occurred (1 due to progressive disease and 1 due to functional decline with stable imaging). Visual outcomes were heterogeneous: 1 patient maintained intact vision; others had intermittent diplopia, bitemporal hemianopsia, or unilateral blindness with contralateral impairment. Endocrinopathy was frequent: 3 of 4 survivors had pan-hypopituitarism; 1 had partial deficits (hypothyroidism/amenorrhea). Functional status was impaired in survivors, with the inability to work or study due to fatigue, visual loss, or cognitive issues. Additional toxicities included posttreatment seizures requiring hospitalization (n = 1) and transient dexamethasone for headache (n = 1). Conclusions In carefully selected patients lacking other curative options, modern highly conformal reirradiation can achieve meaningful local control after prior high-dose radiation therapy, but carries an additive risk of visual, endocrine, and functional morbidity. Decisions should be individualized within a multidisciplinary team to identify appropriate cases for reirradiation and to ensure thorough long-term follow-up to manage delayed toxicity.
PURPOSE:The purpose of this retrospective study was to investigate the incidence of MRONJ and its related risk factors in multiple myeloma (MM) patients undergoing dental extractions prior to autologous stem cell transplantation (ASCT). METHODS:This retrospective study evaluated patients treated January 1, 2011, to January 1, 2022. Medical and dental records of 1547 patients referred to the Dental Oncology Clinic at Princess Margaret Cancer Centre were reviewed, with 320 patients meeting the eligibility criteria and included in the analysis. RESULTS:Among 320 patients, patients had on average 3 teeth removed prior to ASCT and 13 (4.1%) developed MRONJ. Periodontal disease was the most common reason for dental extraction among MRONJ cases. Patients prescribed zoledronic acid alone were nearly 5 times more likely to develop MRONJ than patients treated with pamidronate alone, with the highest risk observed in patients who were prescribed pamidronate and later changed to zoledronic acid. Even a single dose of bisphosphonate was sufficient to cause MRONJ following dental extraction and in some cases, onset to MRONJ following extraction was in the span of years. CONCLUSION:The decision to recommend extractions in patients previously exposed to intravenous bisphosphonates should take into account the severity of dental disease versus risk of MRONJ. In particular, the type and duration of bisphosphonate therapy should be considered. When extractions are performed in patients at-risk of MRONJ, they should be warned of the risk (around 4% in this study) and followed for a period appropriate to detect complications.
The optimal adjuvant alkylating chemotherapy regimen for high-risk WHO grade 2 glioma in the molecular era remains uncertain. We evaluated real-world treatment patterns, toxicity, and outcomes following radiotherapy with adjuvant temozolomide (TMZ) or procarbazine, lomustine, and vincristine (PCV) in a multicentre Canadian cohort. PROTECT is a retrospective multicentre cohort study including adults with clinically defined high-risk WHO grade 2 diffuse glioma treated with radiotherapy and adjuvant alkylating chemotherapy. Clinical, molecular, treatment delivery, toxicity, surveillance, and survival data were collected. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method and compared using the log-rank test and Cox regression. A total of 116 patients were included, with a median follow-up of 71 months. Isocitrate dehydrogenase (IDH) mutation was present in 84.6
Artificial intelligence (AI) has the potential to transform health care; however, successful integration of AI into health care requires overcoming obstacles, such as biases in data and AI models, and addressing challenges in generating sufficient clinical evidence for deployment. In this Viewpoint, we present a community-based, actionable framework for responsible and ethical development, deployment, and integration of AI-based solutions in health care, emphasising bias mitigation and clinical evidence generation. Our framework is intended for all members of the health-care team who interact with AI-based solutions, including software developers, data scientists, researchers, clinicians, hospital administrators, and institutional ethics and regulatory teams. We critically discuss the challenges associated with the use of such AI frameworks in health care. The framework, informed by multidisciplinary expertise, consists of four stages: (1) problem identification and study design, (2) model training and development, (3) silent deployment and clinical evaluation, and (4) operational deployment and lifecycle monitoring. This framework aligns with reporting standards such as SPIRIT-AI, CONSORT-AI, and TRIPOD+AI, offering practical steps for addressing biases, ensuring fairness, and validating clinical effectiveness. The framework provides action-oriented guidelines that can be used by institutions to support the ethical and efficient integration of AI into health care and equitable patient outcomes, either directly or by tailoring the guidelines with institution-specific resources.
ABSTRACT:Immunodeficiency-associated primary central nervous system lymphoma (ID-PCNSL) represents a clinicopathologically distinct PCNSL subtype, for which large studies and prognostic models are lacking. To address this gap, the International PCNSL Collaborative Group conducted a retrospective multicenter study, integrating clinical, radiological, and pathological data from 308 ID-PCNSL cases, diagnosed at 23 participating sites in 7 countries. Preexisting immunodeficiency included administration of immunosuppressants for transplantation (41.2%) or autoimmunity (36.7%) and HIV infection (21.7%). All tumors were diffuse large B-cell lymphomas, with Epstein-Barr virus (EBV) detected in 79.2%. Immune reconstitution together with rituximab and methotrexate-based chemotherapy was associated with the highest response rates and prolonged progression-free survival, irrespective of immunodeficiency subtype and EBV status. Survival outcomes were highly variable, with a 54-month median overall survival. Multivariable Cox regression identified age (per year increment; hazard ratio [HR], 1.05 (95% confidence interval [CI], 1.02-1.07); P< .001), Karnofsky performance status (KPS) <70 (HR, 3.10; 95% CI, 1.67-5.87; P< .001), and EBV positivity (HR, 3.26; 95% CI, 1.47-7.33; P = .004) as prognostic factors for overall survival. A prognostic score was developed based on the sum of these adverse variables (age >60 years, KPS <70, EBV positivity). Stratification by this score yielded median survival times of 135, 29, and 3 months in patients with up to 1, 2, and 3 unfavorable markers (P< .0001). It allowed improved prognostic stratification of ID-PCNSL as compared with the Memorial Sloan Kettering Cancer Center and International Extranodal Lymphoma Study Group models developed for immunocompetent PCNSL. Collectively, this large international cohort defines clinicobiological features of ID-PCNSL and introduces a prognostic system with potential to guide future management.